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Summary Zonisamide is a benzisoxazole-based compound ﬁrst synthesized in the
early 1970s by the research laboratories of Dainippon Pharmaceutical Company in Os-
aka, Japan. Identiﬁed as an anticonvulsant during exploratory research, zonisamide
has since been characterized as having broad-spectrum antiepilepsy and neuropro-
tective effects. Early clinical studies in Japan demonstrated that zonisamide has a
long elimination half-life and is well tolerated; Phase II and III clinical trials estab-
lished the drug’s efﬁcacy and safety for the treatment of partial and generalized
seizures. In 1989, zonisamide was approved and marketed in Japan under the trade
name of Excegran®. Data from postmarketing surveillance studies and clinical ob-
servations over 10 years of use have continued to support zonisamide’s efﬁcacy and
safety, identiﬁed its usefulness as monotherapy, and characterized its effectiveness
for various seizure types and epilepsy syndromes.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Zonisamide, a benzisoxazole-based compound, was
ﬁrst synthesized in 1974 by the research labora-
tories of Dainippon Pharmaceutical Company dur-
ing exploratory research on drugs for psychiatric
disorders. Preclinical studies in laboratory ani-
mals showed that the range of zonisamide plasma
concentrations suppressed maximal electroshock
seizures, and that the occurrence of neurological
adverse effects was broader than the range ob-
served for phenytoin or carbamazepine.1 These
results suggested that zonisamide might also have
a broader therapeutic range in humans compared
to other antiepilepsy drugs (AEDs). The mecha-
nisms by which zonisamide halts seizure activity
are not fully understood, but are thought to involve
suppression of voltage-dependent sodium channels
and T-type calcium channels.2,3
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Animal experiments have also demonstrated
that zonisamide has neuroprotective effects. Zon-
isamide can prevent incipient cerebral infarc-
tion in an ischemia/reperfusion model,4 and can
inhibit degeneration of dopaminergic neurons
in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-derived model of Parkinson’s disease.5
Such effects have not been observed with car-
bamazepine or valproate, and suggest that zon-
isamide may have a free-radical scavenging effect.
The neuroprotective effects of zonisamide seem to
be distinct from its antiepilepsy effects.
Phase I through III trials in Japan
Phase I trials of zonisamide began in September
1979 at the National Epilepsy Center in Shizuoka.
These trials, which involved healthy male volun-
teers, showed that zonisamide has a long elimina-
tion half-life and is well tolerated.6
Phase II trials commenced in 1985, followed by
Phase III trials. Among the trials was a double-
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blind study in which zonisamide was used to treat
adult patients with partial seizures; carbamazepine
served as the control drug.7 Thirty-four institutions
participated in this study. The data showed that dur-
ing a 16-week observation period, the zonisamide
treatment group exhibited improvement rates in
seizure frequency, deﬁned as >50% reduction in
seizure frequency from the baseline, that were
almost equal to those seen with carbamazepine
treatment. In addition, zonisamide’s safety proﬁle
was superior to carbamazepine. In another study
that compared zonisamide and valproate in chil-
dren with convulsive or nonconvulsive generalized
seizures over 8 weeks of treatment, zonisamide
efﬁcacy was equivalent to that of valproate.8
A total of 1008 patients were engaged in Phase
II and III trials of zonisamide. Examination of data
for the 1008 patients showed that 72% of patients
receiving zonisamide monotherapy experienced a
>50% reduction in seizure frequency from the base-
line (i.e., improvement rate). Improvement rates
in zonisamide-treated patients were 81% for simple
and complex seizures, and 67% for secondarily gen-
eralized tonic—clonic seizures.
Among the same 1008 patients, adverse effects
were observed in 573 (52%), and zonisamide was
discontinued in 185 (18%). Principal adverse ef-
fects were drowsiness (24%), ataxia (13%), loss of
appetite (11%), gastrointestinal symptoms (7%), de-
crease in spontaneity (6%), andmental slowing (5%).
Renal calculi were found in two patients, both of
whom had a positive family history of kidney stones.
The stones were discharged spontaneously, and
the stone from one of the patients was a calcium
salt.9
Application for approval to manufacture zon-
isamide in Japan was made in December 1987, and
marketing was approved in March 1989. In June
1989, zonisamide was marketed under the trade
name of Excegran®. A brief discussion of the current
status of zonisamide in the Japanese AED market is
provided in the sidebar. In June 1992, zonisamide
was introduced in the South Korean market.
Postmarketing studies in Japan
Following the debut of zonisamide on the Japanese
market, Dainippon initiated postmarketing surveil-
lance. This surveillance was comprised of two
studies–—a general retrospective study and a
prospective survey on long-term use. The retro-
spective study lasted 5 years–—from April 1989 to
March 1994–—and data were collected for a total
of 4028 patients from 459 hospitals nationwide. To
assess the long-term safety and efﬁcacy of zon-
isamide for treatment of epilepsy, the prospective
survey studied patients for whom zonisamide had
been administered for >1 year to ≤3 years. Safety
data were collected for 1512 patients. Results from
these studies will be detailed elsewhere in this
supplement.
Personal clinical experience
In my personal experience in treating patients
with various epileptic syndromes, I have found
zonisamide useful as monotherapy, both for adults
and pediatric patients. In addition, zonisamide is
effective for simple and complex partial seizures,
with or without partial-onset generalized tonic—
clonic seizures. It is also effective for generalized
tonic—clonic seizures, tonic seizures, atypical ab-
sence seizures, infantile spasms, and progressive
myoclonus epilepsies. However, zonisamide may
or may not be effective for myoclonic seizures of
idiopathic generalized epilepsy.
Conclusion
Zonisamide clearly plays a key role in the treat-
ment of epilepsy in Japan. However, Japan needs
additional AEDs. Since zonisamide’s introduction
in 1989, no new AEDs have been approved in
Japan despite extensive clinical trials of numerous
AEDs, including felbamate, gabapentin, lamotrig-
ine, tiagabine, and topiramate, all of which have
received approval in other countries. The chief
barrier to the introduction of new AEDs in Japan
seems to be a drug administration bureaucracy
that can greatly delay the approval process and the
launch of new AEDs on the Japanese market. This
has been a tremendous problem since the launch
of zonisamide in Japan.
Zonisamide and antiepilepsy drug market
in Japan
In 1998, the AED market totaled 26.7 billion yen
on a drug price basis. Valproate held about 50% of
the market, followed by carbamazepine and zon-
isamide, each with a share of slightly more than
12%. Since its introduction in 1989, zonisamide has
shown a steady annual growth in market share, in-
cluding a 9.5% share of the AED market in 1994,
progressing to a 10.9% share in 1996 and a 12.1%
share in 1998 (Table 1). These facts indicate an ap-
praisal and acceptance of zonisamide and demon-
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Table 1 Zonisamide market penetration 1994—
1998.
Year Total AED sales
(, in billions)a
ZNS market share
(% total sales)a
1994 25.7 9.5
1995 26.4 10.2
1996 26.8 10.9
1997 27.3 11.7
1998 26.7 12.1
a Figures are approximations.
strate zonisamide’s steady, albeit gradual, penetra-
tion of the Japanese AED market.
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